107 related articles for article (PubMed ID: 26037349)
1. [Subcellular localization of ataxin-3 and its effect on the morphology of cytoplasmic organoids].
Wei F; Xiao H; Hu Z; Zhang H; Wang C; Dai H; Tang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Jun; 32(3):353-7. PubMed ID: 26037349
[TBL] [Abstract][Full Text] [Related]
2. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
3. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
4. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
6. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
[TBL] [Abstract][Full Text] [Related]
7. Identification and functional dissection of localization signals within ataxin-3.
Antony PM; Mäntele S; Mollenkopf P; Boy J; Kehlenbach RH; Riess O; Schmidt T
Neurobiol Dis; 2009 Nov; 36(2):280-92. PubMed ID: 19660550
[TBL] [Abstract][Full Text] [Related]
8. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
[TBL] [Abstract][Full Text] [Related]
9. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
10. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.
Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U
Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
12. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
13. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
14. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
15. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous intracellular localization and expression of ataxin-3.
Trottier Y; Cancel G; An-Gourfinkel I; Lutz Y; Weber C; Brice A; Hirsch E; Mandel JL
Neurobiol Dis; 1998 Nov; 5(5):335-47. PubMed ID: 10069576
[TBL] [Abstract][Full Text] [Related]
17. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
18. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
19. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
20. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3.
Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO
Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]